These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38651408)

  • 1. Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies.
    Sun M; Li Y; Zheng H; Shao Y
    Front Immunol; 2016; 7():391. PubMed ID: 27746780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyfunctionality of broadly neutralizing HIV-1 antibodies.
    Vrignaud LL; Schwartz O; Bruel T
    Curr Opin HIV AIDS; 2023 Jul; 18(4):178-183. PubMed ID: 37249912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond bNAbs: Uses, Risks, and Opportunities for Therapeutic Application of Non-Neutralising Antibodies in Viral Infection.
    Mader K; Dustin LB
    Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38651408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
    Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyreactivity and autoreactivity among HIV-1 antibodies.
    Liu M; Yang G; Wiehe K; Nicely NI; Vandergrift NA; Rountree W; Bonsignori M; Alam SM; Gao J; Haynes BF; Kelsoe G
    J Virol; 2015 Jan; 89(1):784-98. PubMed ID: 25355869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell immunodominance in primary hepatitis C virus infection.
    Brasher NA; Eltahla AA; Underwood A; Boo I; Rizzetto S; Walker MR; Rodrigo C; Luciani F; Maher L; Drummer HE; Tedla N; Lloyd AR; Bull RA
    J Hepatol; 2020 Apr; 72(4):670-679. PubMed ID: 31785346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.
    Horwitz JA; Bar-On Y; Lu CL; Fera D; Lockhart AAK; Lorenzi JCC; Nogueira L; Golijanin J; Scheid JF; Seaman MS; Gazumyan A; Zolla-Pazner S; Nussenzweig MC
    Cell; 2017 Aug; 170(4):637-648.e10. PubMed ID: 28757252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody inhibition of influenza A virus assembly and release.
    He Y; Guo Z; Subiaur S; Benegal A; Vahey MD
    J Virol; 2024 Feb; 98(2):e0139823. PubMed ID: 38179944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadly neutralizing antibodies to combat influenza virus infection.
    Sun X; Ma H; Wang X; Bao Z; Tang S; Yi C; Sun B
    Antiviral Res; 2024 Jan; 221():105785. PubMed ID: 38145757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses.
    Rijnink WF; Stadlbauer D; Puente-Massaguer E; Okba NMA; Kirkpatrick Roubidoux E; Strohmeier S; Mudd PA; Schmitz A; Ellebedy A; McMahon M; Krammer F
    J Virol; 2023 Nov; 97(11):e0164622. PubMed ID: 37916834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers.
    Biswas S; Mandal G; Anadon CM; Chaurio RA; Lopez-Bailon LU; Nagy MZ; Mine JA; Hänggi K; Sprenger KB; Innamarato P; Harro CM; Powers JJ; Johnson J; Fang B; Eysha M; Nan X; Li R; Perez BA; Curiel TJ; Yu X; Rodriguez PC; Conejo-Garcia JR
    Immunity; 2023 Nov; 56(11):2570-2583.e6. PubMed ID: 37909039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective mechanisms of nonneutralizing antiviral antibodies.
    Chandler TL; Yang A; Otero CE; Permar SR; Caddy SL
    PLoS Pathog; 2023 Oct; 19(10):e1011670. PubMed ID: 37796829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel B-Cell Epitopes of Non-Neutralizing Antibodies in the Receptor-Binding Domain of the SARS-CoV-2 S-Protein with Different Effects on the Severity of COVID-19.
    Matveev AL; Pyankov OV; Khlusevich YA; Tyazhelkova OV; Emelyanova LA; Timofeeva AM; Shipovalov AV; Chechushkov AV; Zaitseva NS; Kudrov GA; Yusubalieva GM; Yussubaliyeva SM; Zhukova OA; Tikunov AY; Baklaushev VP; Sedykh SE; Lifshits GI; Tikunova NV
    Biochemistry (Mosc); 2023 Sep; 88(9):1205-1214. PubMed ID: 37770389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review: Understanding Molecular Mechanisms of Antibody-Dependent Enhancement in Viral Infections.
    Sawant J; Patil A; Kurle S
    Vaccines (Basel); 2023 Jul; 11(7):. PubMed ID: 37515055
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.